OBJECTIVE: The aim of this double-blind, placebo-controlled study was to evaluate the efficacy and tolerability of ziprasidone in the treatment of adult patients with borderline personality disorder. METHOD:Sixty DSM-IV borderline personality disorder patients were included from March 2004 to April 2006 in a 12-week, single-center, double-blind, placebo-controlled study. The subjects were randomly assigned to ziprasidone or placebo in a 1:1 ratio following a 2-week baseline period. The Clinical Global Impressions scale for use in borderline personality disorder patients (CGI-BPD) was the primary outcome measure, and other scales and self-reports related to affect, behavior, psychosis, general psychopathology domains, and clinical safety were included. RESULTS: Analysis of variance indicated no statistically significant differences between ziprasidone and placebo in the CGI-BPD. Nor were significant differences observed between groups in depressive, anxiety, psychotic, or impulsive symptoms. The mean daily dose of ziprasidone was 84.1 mg/day (SD = 54.8; range, 40-200). The drug was seen to be safe, and no serious adverse effects were observed. CONCLUSION: This trial failed to show a significant effect of ziprasidone in patients with borderline personality disorder. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00635921.
RCT Entities:
OBJECTIVE: The aim of this double-blind, placebo-controlled study was to evaluate the efficacy and tolerability of ziprasidone in the treatment of adult patients with borderline personality disorder. METHOD: Sixty DSM-IV borderline personality disorderpatients were included from March 2004 to April 2006 in a 12-week, single-center, double-blind, placebo-controlled study. The subjects were randomly assigned to ziprasidone or placebo in a 1:1 ratio following a 2-week baseline period. The Clinical Global Impressions scale for use in borderline personality disorderpatients (CGI-BPD) was the primary outcome measure, and other scales and self-reports related to affect, behavior, psychosis, general psychopathology domains, and clinical safety were included. RESULTS: Analysis of variance indicated no statistically significant differences between ziprasidone and placebo in the CGI-BPD. Nor were significant differences observed between groups in depressive, anxiety, psychotic, or impulsive symptoms. The mean daily dose of ziprasidone was 84.1 mg/day (SD = 54.8; range, 40-200). The drug was seen to be safe, and no serious adverse effects were observed. CONCLUSION: This trial failed to show a significant effect of ziprasidone in patients with borderline personality disorder. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00635921.
Authors: Márcio G Soeiro-DE-Souza; Vasco Videira Dias; Giovanni Missio; Vicent Balanzá-Martinez; Leandro Valiengo; André F Carvalho; Ricardo Alberto Moreno Journal: Exp Ther Med Date: 2015-01-23 Impact factor: 2.447
Authors: Christina W Slotema; Jan Dirk Blom; Marieke B A Niemantsverdriet; Iris E C Sommer Journal: Front Psychiatry Date: 2018-07-31 Impact factor: 4.157
Authors: Jon E Grant; Stephanie Valle; Eve Chesivoir; Dustin Ehsan; Samuel R Chamberlain Journal: Br J Psychiatry Date: 2021-11-17 Impact factor: 9.319